Advances in Antioxidant Applications for Combating (131)I Side Effects in Thyroid Cancer Treatment

Thyroid cancer is the most common endocrine cancer, and its prevalence has been increasing for decades. Approx. 95% of differentiated thyroid carcinomas are treated using (131)iodine ((131)I), a radionuclide with a half-life of 8 days, to achieve optimal thyroid residual ablation following thyroidec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li, Ma, Jiahui, Lei, Pengyu, Yi, Jia, Ma, Yilei, Huang, Zhongke, Wang, Tingjue, Ping, Haiyan, Ruan, Danping, Sun, Da, Pan, Hongying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303824/
https://www.ncbi.nlm.nih.gov/pubmed/37368629
http://dx.doi.org/10.3390/toxics11060529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303824/
https://www.ncbi.nlm.nih.gov/pubmed/37368629
http://dx.doi.org/10.3390/toxics11060529

Ejemplares similares